作为双重抑制方法,EGFR针对PhosTACs揭示了下游信号的差异性
Zhenyi Hu1,2, Po-Han Chen1,3,4, Wenxue Li5
1Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06511, USA.
Science advances
|March 27, 2024
概括
我们开发了酸化向嵌合体 (PhosTACs),用于向蛋白质脱. 这些分子有效抑制像EGFR这样的激酶,通过诱导细胞亡和降低细胞活力,在癌症治疗中显示出潜力.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 向性蛋白质脱化 (TPDephos) 对于细胞信号传递至关重要.
- 受体氨酸激酶 (RTKs) 是细胞生长的关键调节剂,在癌症中经常受到失调.
- 现有的RTK抑制剂 (RTKI) 主要阻断激酶活性,但去酸化提供了一个替代的抑制策略.
研究的目的:
- 开发一种新的异构功能方法,酸化向嵌合体 (PhosTACs),用于向蛋白质脱.
- 将RTKI效应与活性酸酶介导的脱化结合起来,以实现双酶抑制.
- 研究PhosTACs对表皮生长因子受体 (EGFR) 的疗效及其对癌细胞信号传递和活力的影响.
主要方法:
- 开发基于氨酸酸酶的PhosTACs用于向脱.
- 利用蛋白质组方法来分析由PhosTACs诱导的全蛋白质组信号变化.
- 采用一种对突变EGFR具有选择性的共价PhosTAC.
- 评估对PhosTAC治疗的反应中癌细胞活力和亡诱导.
主要成果:
- 使用PhosTACs证明了有效的表皮生长因子受体 (EGFR) 氨酸脱化.
- 与传统的TKI如gefitinib相比,通过PhosTACs识别了差异信号通路的抑制.
- 开发了一种ovalent PhosTAC,针对突变EGFR,显示出对失调EGFR的抑制潜力.
- EGFR PhosTACs诱导了细胞亡并降低了癌细胞活力,特别是在长期治疗期间.
结论:
- PhosTACs代表了针对蛋白质脱的新策略,为酶抑制提供了一种补充方法.
- 这种双功能分子的实用性扩大了针对由RTK失调驱动的癌症的治疗策略的范围.
- PhosTACs在调节RTK活动方面显示出显著的潜力,并为癌症治疗提供了一个有前途的途径.
相关概念视频
01:22Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
01:19Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K